Diagenode

N6-methyladenosine (m6A) Antibody

Catalog Number
Format
Price
C15200082-50
50 μg/ 25 μl
$380.00
  Bulk order
Other format



Monoclonal antibody raised in mouse against N6-methyladenosine (m6A) conjugated to BSA.

Lot001
Concentration2 μg/μl
Species reactivityHuman, mouse, other (wide range)
TypeMonoclonal
PurityProtein A purified monoclonal antibody.
HostMouse
Storage ConditionsStore at -20°C; for long storage, store at -80°C. Avoid multiple freeze-thaw cycles.
Storage BufferPBS containing 0.05% azide.
PrecautionsThis product is for research use only. Not for use in diagnostic or therapeutic procedures.
Applications Suggested dilution References
RIP* 2 µg per IP Fig 1, 2
Dot Blotting 1:500 Fig 3, 4

* Please note that the optimal antibody amount per IP should be determined by the end-user. We recommend testing 1-10 µg per IP.

  • Validation Data

    N6-methyladenosine (m6A) antibody for RIP

    Figure 1. RNA immunoprecipitation using the Diagenode monoclonal antibody directed against m6A
    RNA Immunoprecipitation was performed on 40 µg HeLa total RNA spiked with 0.5 µg of an in vitro prepared transcript containing 6mA nucleotides, using 2 µg of the Diagenode monoclonal m6A antibody (cat. nr. C15200082). An equal amount of IgG was used as negative control. The immunoprecipitated RNA was subsequently analyzed by qRT-PCR with primers specific for the transcript and for an intergenic region, used as negative control. Figure 1 shows the recovery, expressed as a % of input (the relative amount of immunoprecipitated DNA compared to input DNA after qPCR analysis).

    N6-methyladenosine (m6A) antibody for RNA immunoprecipitation

    Figure 2. RNA immunoprecipitation using the Diagenode monoclonal antibody directed against m6A
    Immunoprecipitation was performed on two radiolabelled synthetic RNA oligo’s, a 250 nt oligo containing m6A nucleotides and a 350 nt unmethylated control, using the Diagenode monoclonal m6A antibody (cat. nr. C15200082). The immunoprecipitated fraction is shown in lane 3; lane 2 shows the non bound fraction, whereas the input is shown in lane 1.

    N6-methyladenosine (m6A) antibody for dot blot

    Figure 3. Dot blot analysis using the Diagenode monoclonal antibody directed against m6A
    To demonstrate the specificity of the Diagenode monoclonal antibody against m6A (Cat. No. C15200082), a Dot Blot analysis was performed using an m6A containing, a non-methylated control and a non-methylated polyA control synthetic RNA oligonucleotide.

    N6-methyladenosine (m6A) antibody validated in dot blot

    Figure 4. Dot blot analysis using the Diagenode monoclonal antibody directed against m6A
    Dot Blot analysis was performed using a synthetic DNA oligonucleotide containing different m6A modified bases and a negative control. 100 to 4 pmol of the respective oligo’s were spotted on the membrane. The antibody was diluted of 1:500 in TBS-T containing 10 % skimmed milk and 1% BSA. Figure 4 shows a high specificity of the antibody for the modified oligonucleotide.

  • Target Description

    N6-methyladenosine (m6A) is a modified base which is abundant in mRNA in most eukaryotes but also has been found in tRNA’s, rRNA’s, snRNA’s and in long non-coding RNA’s. Adenosine methylation is catalyzed by m6A methyltransferase, a large protein complex which has a preference for the consensus sequence GGACU. In human, the m6A modification has been identified in more than 7000 genes. It is preferably present around stop codons and in the 3’ UTR but has not been observed in poly A tails. m6A is dynamically regulated both throughout development and in response to cellular stimuli. Levels are significantly higher in adulthood than during embryonic development. Although the presence of m6A in RNA was identified several years ago, it’s physiological significance remains largely unknown. It has been proposed to affect mRNA processing and export from nucleus to cytoplasm. Recently, it was shown that mutations in the m6A demethylase gene FTO, which cause a decrease of m6A levels, are associated with an increased risk for obesity and type 2 diabetes.

  •  Applications
    RIP
    RIP Read more
    DB
    Dot blotting Read more
  •  Documents
    m6A monoclonal antibody C15200082 DATASHEET
    Monoclonal antibody raised in mouse against N6-methyladenosine (m6A) conjugated to BSA.
    Download
    Antibodies you can trust POSTER
    Epigenetic research tools have evolved over time from endpoint PCR to qPCR to the analyses of lar...
    Download
    Epigenetic Antibodies Brochure BROCHURE
    More than in any other immuoprecipitation assays, quality antibodies are critical tools in many e...
    Download
  •  Safety sheets
    N6 methyladenosine(m6A) Antibody SDS US en Download
    N6 methyladenosine(m6A) Antibody SDS GB en Download
    N6 methyladenosine(m6A) Antibody SDS BE fr Download
    N6 methyladenosine(m6A) Antibody SDS FR fr Download
    N6 methyladenosine(m6A) Antibody SDS ES es Download
    N6 methyladenosine(m6A) Antibody SDS DE de Download
    N6 methyladenosine(m6A) Antibody SDS JP ja Download
    N6 methyladenosine(m6A) Antibody SDS BE nl Download
  •  Publications

    How to properly cite this product in your work

    Diagenode strongly recommends using this: N6-methyladenosine (m6A) Antibody (Diagenode Cat# C15200082-50 Lot# 001). Click here to copy to clipboard.

    Using our products in your publication? Let us know!

    Single-cell m6A mapping in vivo using picoMeRIP-seq
    Li Y. et al.
    Current N-methyladenosine (mA) mapping methods need large amounts of RNA or are limited to cultured cells. Through optimized sample recovery and signal-to-noise ratio, we developed picogram-scale mA RNA immunoprecipitation and sequencing (picoMeRIP-seq) for studying mA in vivo in single cells and scarce cell types u...

    Evaluation of N<sup>6</sup>-adenine DNA-immunoprecipitation-basedgenomic profiling in eukaryotes
    Debo Brian M. et al.
    The detection of low-abundance DNA N6-methyladenine (DNA-m6A) remains challenging, limiting our understanding of this novel base in eukaryotes. To address this, we introduce an approach for systematically validating the selectivity and sensitivity of antibody-based DNA-m6A methods, revealing most commercial antibodi...

Events

  • AACR 2024
    San Diego, California, USA
    Apr 5-Apr 10, 2024
 See all events

News

 See all news


The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.


       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics